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Cell and gene therapy clinical trials began more than 40
years ago. At some institutions cellular therapy labora-
tories were started to support marrow transplantation.
These early laboratories removed red blood cells and
plasma from aspirated bone marrow that was used for
allogeneic transplants, cyropreserved autologous mar-
row, depleted T cells from allogeneic grafts and depleted
leukemic or cancerous cells from autologous grafts [1].
At other institutions cellular therapy laboratories were
started to isolate and expand tumor infiltrating lympho-
cytes (TIL) that were used as investigational treatments
for patients with melanoma or to prepare transfected
autologous lymphocytes to treat severe combined
immune deficiencies.
For many years cellular and gene therapies were pri-
marily highly experimental therapies which were devel-
oped and used in highly specialized academic health
care centers. Now these forms of therapies are used in
numerous clinical trials throughout the US and world-
wide. While the field has advanced, progress has been
slow. Some therapies have not been effective and some
have been associated with unacceptable adverse out
comes. However, both cell and gene therapies have now
become important potential therapies for incurable
diseases.
Hematopoietic stem cell transplants have changed dra-
matically and have become very successful for hemato-
poietic reconstitution. Hematopoietic stem cell
transplants now make use of marrow, mobilized periph-
eral blood stem cells and umbilical cord blood for trans-
plants involving HLA matched siblings and unrelated
subjects as well as autologous transplants. Recently,
there have been important advances in immune therapy
of cancer. Immune therapy for melanoma protocols that
involve TIL make use of lymphodepletion and autolo-
gous CD34+ cell rescue have been reported to result in
a greater than 50% objective clinical response rates [2].
Gene therapy is being used as investigational treatment
for severe combined immune deficiency (SCID), Leber’s
Congenital Amaurosis (LCA) and chronic granuloma-
tous disease (CGD) [3] and may soon be used in clinical
trials to treat sickle cell disease.
The successful clinical results of some cellular and
gene therapy clinical trials and the increased under-
standing of immunology, cancer, and stem cell biology
have lead to the development of many potential new
therapies. Natural killer (NK) cells and dendritic cells
(DCs) are important parts of many cancer immune ther-
apy investigational protocols. Genetically engineered
T cells and DCs are being tested for immune therapy
for cancer. Vectors containing tumor reactive T cell
receptors are being introduced into T cells. Chimeric
receptors containing antibodies specific to antigens
expressed by leukemic cells along with T cell costimula-
tory molecules are being transferred into T cells that are
being used therapeutically. Artificial antigen presenting
cells are being made by introducing costimulatory mole-
cules into cell lines and these cells are being used to
expand cytotoxic T cells in vitro.
Regenerative medicine is an emerging new field. Mar-
row and mobilized PBSCs injected into ischemic myo-
cardium was been reported to increase cardiac function
[4]. Meschenchymal stem cells or bone marrow stromal
cells (BMSCs) are also being used to as investigational
treatments for ischemic heart disease. BMSCs are also
being tested for the treatment of acute renal failure,
nerve injury, acute GVHD and autoimmune disease [5].
Induced pluripotent stem (IPS) cells harbor great poten-
tial for regenerative medicine applications and for a
number of hematopoietic and immune disorders. Work
with IPS cells is moving quickly, but the routine clinical
application of IPS cells is still many years away.
Translational studies have been and will continue to
be critical to progress in cellular and gene therapy. The
converging nature of gene therapy, immune therapy for
cancer, HSC transplantation, regenerative medicine and
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exchange of information essential. The goal the JTM
Cell and Gene Therapy Section is to advance this field
by reporting the results of translational medicine studies
and by being a forum for the exchange and discussion
of new information, ideas and hypothesis. We welcome
contributions from all those participating in this field;
clinicians, scientists, and engineers from academia,
industry and the regulatory community.
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